The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects

Conditions: Nonalcoholic Fatty Liver Disease Interventions: Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part One; Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two; Drug: Placebo - Study Part One; Drug: Placebo - Study Part Two Sponsors: ChemomAb Ltd. Completed

https://clinicaltrials.gov/study/NCT06044467

Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials